BillionToOne, Inc. Class A Common Stock
NASDAQ: BLLN · HEALTHCARE · DIAGNOSTICS & RESEARCH
Updated 2026-06-05
BillionToOne, Inc. Class A Common Stock (BLLN) Financial statements
SEC filings — annual and quarterly data.
Margin trends — annual
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2023 | $71.73M | $-82.68M | 24.13% | -96.89% | -115.27% |
| 2024 | $152.58M | $-41.57M | 53.03% | -30.90% | -27.24% |
| 2025 | $305.11M | $7.45M | 68.32% | 5.25% | 2.44% |
Frequently asked questions
What is BillionToOne, Inc. Class A Common Stock's revenue?
BillionToOne, Inc. Class A Common Stock's trailing twelve-month revenue is $354.54M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is BLLN?
In its most recent fiscal year, BLLN ran a gross margin of 68.32%, an operating margin of 5.25%, and a net margin of 2.44%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does BLLN generate?
BLLN produced $15.71M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is BLLN's balance sheet healthy?
BLLN holds $495.98M in cash and equivalents against $57.23M in long-term debt, on $480.11M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.